Previous Close | 1.2700 |
Open | 1.2850 |
Bid | 1.2700 x 1800 |
Ask | 1.2800 x 900 |
Day's Range | 1.2700 - 1.2900 |
52 Week Range | 1.0400 - 2.0000 |
Volume | |
Avg. Volume | 106,054 |
Market Cap | 14.973M |
Beta (5Y Monthly) | 1.17 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5700 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for NNVC
By David Bautz, PhD AMEX:NNVC In June 2023, NanoViricides, Inc. (AMEX:NNVC) announced the initiation of a Phase 1a/b safety and efficacy clinical trial of NV-CoV-2, the company’s development candidate for the treatment of COVID-19 and other coronavirus infections. The trial is evaluating two oral formulations of the compound: NV-CoV-2 oral syrup and Nv-CoV-2 oral gummies. This is an important
Proactive research analyst John Savin speaks to Thomas Warner after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC).
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, is progressing successfully.